A2B395
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for A2B395, covering 2025-09-09 to 2025-09-09. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression [Phase 1, Phase 2]